Deliberazione
Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to evaluate efficacy and safety of secukinumab administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with poymyalgia rheumatica (PMR)” - Codice Protocollo CAIN457C22301
N° 544
del 05/10/2023
